ES8800601A1 - Un procedimiento para preparar una formulacion farmaceutica liofilizada de activador de plasminogeno de tejidro (t-pa) - Google Patents

Un procedimiento para preparar una formulacion farmaceutica liofilizada de activador de plasminogeno de tejidro (t-pa)

Info

Publication number
ES8800601A1
ES8800601A1 ES555353A ES555353A ES8800601A1 ES 8800601 A1 ES8800601 A1 ES 8800601A1 ES 555353 A ES555353 A ES 555353A ES 555353 A ES555353 A ES 555353A ES 8800601 A1 ES8800601 A1 ES 8800601A1
Authority
ES
Spain
Prior art keywords
pharmaceutical formulation
plasminogen activator
tissue plasminogen
preparing
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES555353A
Other languages
English (en)
Spanish (es)
Other versions
ES555353A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858513358A external-priority patent/GB8513358D0/en
Priority claimed from GB858521705A external-priority patent/GB8521705D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of ES8800601A1 publication Critical patent/ES8800601A1/es
Publication of ES555353A0 publication Critical patent/ES555353A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES555353A 1985-05-28 1986-05-27 Un procedimiento para preparar una formulacion farmaceutica liofilizada de activador de plasminogeno de tejidro (t-pa) Expired ES8800601A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858513358A GB8513358D0 (en) 1985-05-28 1985-05-28 Formulation
GB858521705A GB8521705D0 (en) 1985-08-31 1985-08-31 Formulation

Publications (2)

Publication Number Publication Date
ES8800601A1 true ES8800601A1 (es) 1987-11-16
ES555353A0 ES555353A0 (es) 1987-11-16

Family

ID=26289290

Family Applications (2)

Application Number Title Priority Date Filing Date
ES555353A Expired ES8800601A1 (es) 1985-05-28 1986-05-27 Un procedimiento para preparar una formulacion farmaceutica liofilizada de activador de plasminogeno de tejidro (t-pa)
ES557374A Expired ES8802439A1 (es) 1985-05-28 1987-02-10 Un procedimiento para preparar una sal fisiologicamente aceptable de activador de plasminogeno de tejido (t-pa).

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES557374A Expired ES8802439A1 (es) 1985-05-28 1987-02-10 Un procedimiento para preparar una sal fisiologicamente aceptable de activador de plasminogeno de tejido (t-pa).

Country Status (22)

Country Link
US (2) US4929444A (cg-RX-API-DMAC7.html)
JP (1) JPH0759517B2 (cg-RX-API-DMAC7.html)
AU (1) AU567236B2 (cg-RX-API-DMAC7.html)
BE (1) BE904830A (cg-RX-API-DMAC7.html)
CA (1) CA1300008C (cg-RX-API-DMAC7.html)
CH (1) CH665356A5 (cg-RX-API-DMAC7.html)
DE (1) DE3617752A1 (cg-RX-API-DMAC7.html)
DK (1) DK163173C (cg-RX-API-DMAC7.html)
ES (2) ES8800601A1 (cg-RX-API-DMAC7.html)
FI (1) FI85335C (cg-RX-API-DMAC7.html)
FR (1) FR2583984B1 (cg-RX-API-DMAC7.html)
GB (1) GB2176702B (cg-RX-API-DMAC7.html)
GR (1) GR861366B (cg-RX-API-DMAC7.html)
HU (1) HU195733B (cg-RX-API-DMAC7.html)
IL (1) IL78938A (cg-RX-API-DMAC7.html)
IT (1) IT1191926B (cg-RX-API-DMAC7.html)
LU (1) LU86444A1 (cg-RX-API-DMAC7.html)
NL (1) NL8601355A (cg-RX-API-DMAC7.html)
NO (1) NO171345C (cg-RX-API-DMAC7.html)
NZ (1) NZ216307A (cg-RX-API-DMAC7.html)
PT (1) PT82646B (cg-RX-API-DMAC7.html)
SE (1) SE462016B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3617753A1 (de) * 1985-05-28 1986-12-04 The Wellcome Foundation Ltd., London Gewebe-plasminogenaktivator, diesen enthaltende pharmazeutische formulierungen sowie ihre herstellung und ihre verwendung in der human- und veterinaermedizin
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
US5034225A (en) * 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
US4976959A (en) * 1986-05-12 1990-12-11 Burroughs Wellcome Co. T-PA and SOD in limiting tissue damage
DK237187A (da) * 1986-05-12 1987-11-13 Wellcome Found Farmaceutisk anvendelse af t-pa
GB8619098D0 (en) * 1986-08-05 1986-09-17 Wellcome Found Combination
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
US5342616A (en) * 1988-06-20 1994-08-30 The Wellcome Foundation Limited Method of administering tissue plasminogen activator
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
DE3835350A1 (de) * 1988-10-17 1990-04-19 Boehringer Mannheim Gmbh Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
WO1992011866A1 (en) * 1991-01-14 1992-07-23 Duke University LAMININ SEQUENCE AS tPA ACTIVATOR
PT786257E (pt) * 1992-06-03 2003-12-31 Genentech Inc Variantes de glicosilacao do activador de plasminogenio tissular com propriedades terapeuticas meloradas
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
KR19990066981A (ko) * 1995-10-23 1999-08-16 윌리엄 뉴우 치료용 맥관형성억제 조성물 및 방법
HUP9900979A3 (en) * 1995-12-13 2001-10-29 Children S Medical Ct Corp Bos Endothelial cell proliferation inhibitor and method of use
EP0827751B1 (en) * 1996-09-06 2003-02-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Medicinal composition containing tissue plasminogen activator and nicotinamide
WO2003022997A2 (en) * 2001-09-07 2003-03-20 Global Biotech Inc. Human tissue urokinase type plasminogen activator formulation
US20040091465A1 (en) * 2002-06-26 2004-05-13 Zachary Yim Therapeutic antiangiogenic compositions and methods
EP1636337A4 (en) * 2003-06-20 2007-07-04 Illumina Inc METHODS AND COMPOSITIONS USEFUL FOR THE AMPLIFICATION AND GENOTYPING OF THE GENOME
US7491263B2 (en) * 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
BRPI0607531A2 (pt) * 2005-04-20 2009-09-15 Hutchinson Fred Cancer Res métodos, composições e artigos de fabricação para intensificação da capacidade de sobrevivência de células, tecidos, órgãos e organismos

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998947A (en) * 1973-11-30 1976-12-21 Pierre Fabre S.A. Process for obtaining a plasminogen activator
FR2252842B1 (cg-RX-API-DMAC7.html) * 1973-12-03 1977-11-04 Fabre Sa Pierre
DE3015699C2 (de) * 1979-04-26 1982-07-15 Asahi Kasei Kogyo K.K., Osaka Herstellung eines Plasminogen-Aktivators
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
JPS5951220A (ja) * 1982-08-02 1984-03-24 Asahi Chem Ind Co Ltd 新規なプラスミノ−ゲン・アクチベ−タ−およびその製法ならびにこれを含有する薬剤
GB2138824B (en) * 1982-10-29 1986-12-31 Mitsui Toatsu Chemicals Novel plasminogen activator process for its preparation and thrombolytic drug containing the same
AU554862B2 (en) * 1982-12-14 1986-09-04 Implico B.V. Plasminogen activator isolated by affinity chromatography
NZ206699A (en) * 1982-12-30 1989-08-29 Bio Response Inc Process for the production of serum independent cell lines
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
DE3584902D1 (de) * 1984-02-29 1992-01-30 Asahi Chemical Ind Waessrige loesung eines darin in erhoehter konzentration aufgeloesten gewebe-plasminogen-aktivators und herstellungsverfahren.
DE3439980A1 (de) * 1984-11-02 1986-05-07 Behringwerke Ag, 3550 Marburg Verfahren zur reinigung sowie pasteurisierung von urokinase
EP0201153A3 (en) * 1985-02-09 1987-10-07 Beecham Group Plc Modified enzyme and process for its preparation
GB8513358D0 (en) * 1985-05-28 1985-07-03 Wellcome Found Formulation
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法

Also Published As

Publication number Publication date
ES557374A0 (es) 1988-06-01
DK246786D0 (da) 1986-05-27
ES8802439A1 (es) 1988-06-01
GB8612780D0 (en) 1986-07-02
NO171345C (no) 1993-03-03
FR2583984B1 (fr) 1989-06-02
DE3617752C2 (cg-RX-API-DMAC7.html) 1988-06-30
LU86444A1 (fr) 1986-12-05
IT1191926B (it) 1988-03-31
AU5796486A (en) 1986-12-04
NO862096L (no) 1986-12-01
HUT41638A (en) 1987-05-28
FI85335B (fi) 1991-12-31
US4929444A (en) 1990-05-29
GR861366B (en) 1986-09-29
JPH06183995A (ja) 1994-07-05
IT8648065A0 (it) 1986-05-27
CH665356A5 (de) 1988-05-13
SE8602405L (sv) 1986-11-29
ES555353A0 (es) 1987-11-16
FI862227L (fi) 1986-11-29
SE8602405D0 (sv) 1986-05-27
DK163173B (da) 1992-02-03
US4968617A (en) 1990-11-06
CA1300008C (en) 1992-05-05
SE462016B (sv) 1990-04-30
NO171345B (no) 1992-11-23
GB2176702A (en) 1987-01-07
PT82646A (en) 1986-06-01
GB2176702B (en) 1989-07-05
FI862227A0 (fi) 1986-05-27
JPH0759517B2 (ja) 1995-06-28
IL78938A0 (en) 1986-09-30
DE3617752A1 (de) 1986-12-04
DK163173C (da) 1992-06-22
AU567236B2 (en) 1987-11-12
HU195733B (en) 1988-07-28
BE904830A (fr) 1986-11-27
NL8601355A (nl) 1986-12-16
PT82646B (pt) 1989-01-30
IL78938A (en) 1993-02-21
FI85335C (fi) 1992-04-10
FR2583984A1 (fr) 1987-01-02
NZ216307A (en) 1989-10-27
DK246786A (da) 1986-11-29

Similar Documents

Publication Publication Date Title
ES8800601A1 (es) Un procedimiento para preparar una formulacion farmaceutica liofilizada de activador de plasminogeno de tejidro (t-pa)
UA34419C2 (uk) Ліофілізований препарат для ін'єкцій та спосіб інгібування росту пухлин
HU902472D0 (en) Process for the production of freeze-dryed pharmaceutical products containing active agents
EP0233013A3 (en) Modified enzyme
NO865079L (no) Fremgangsmaate for fremstilling av stabiliserte humanvevplasminogenaktivatorpreparater.
SE8701921L (sv) Ny farmaceutisk anvendning
FI103111B1 (fi) Menetelmä proteolyyttisen entsyymin inhibiittoreina käyttökelpoisten sakkariinijohdannaisten valmistamiseksi
ES546840A0 (es) Un procedimiento para preparar una sal de acido n-acetil- neuraminico
IE863381L (en) Antibiotics
BG44537A3 (en) Method for preparing of 2- amino- 3- ethoxycarbonylamino- 6- (p- fluor- benzylamino)- piridine gluconate
DE3685052D1 (de) Linolensaeuren enthaltende pharmazeutische und diaet-zusammensetzungen zur behandlung von gutartiger prostatahypertrophie.
AU3744889A (en) Variants of plasminogen activators and processes for their production
HU908361D0 (en) Process for the production of oxazole derivatives and medical preparations containing them as active agents
DE3465880D1 (en) Metabolically active preparations obtained from yeast of any type
AR243602A1 (es) Procedimiento para obtener preparados liquidos acuosos suficientemente estables, de enzimas que tienen accion proteolitica.
NO872671L (no) 4-benzyloksy-3-pyrrolin-2-on-1-yl-acetamid, fremstilling og anvendelse derav.
DE3064798D1 (en) Pentadecapeptide, process for the preparation thereof and immunopotentiating agent
GB1377798A (en) Production of soluble protein
GR3015373T3 (en) 2-Halogen-substituted N-indolyl sulfonic-acid amides, process for their preparation and their pharmaceutical use.
JPS5270084A (en) Polysaccharide ax
FI102844B1 (fi) Menetelmä valmistaa parannettu terapeuttisesti aktiivinen kudosplasminogeenin aktivaattori
SU611620A1 (ru) Способ обезболивани при переломах костей
ZA875954B (en) Oxirane pseudooligasaccharides,a process for their preparation,their use and pharmaceutical preparations
ES2044362T3 (es) Praocedimiento de preparacion de un agente aromatizante.
JPS5272812A (en) Preparation of cephatridin pharmaceuticals for rectal infusion

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19971001